Tags

Type your tag names separated by a space and hit enter

Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.
Addiction. 2012 Feb; 107(2):361-9.A

Abstract

AIMS

To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence.

DESIGN

A double-blind, placebo-controlled 108-day study with random assignment to one of two study conditions: active medication with flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg to day 40) and hydroxazine (50 mg to day 10) versus placebo medication (with active hydroxazine only).

SETTING

Three substance abuse treatment clinics: two in-patient, one out-patient.

PARTICIPANTS

Treatment-seeking, methamphetamine-dependent adults (n = 120).

MEASUREMENTS

Primary outcome was percentage of urine samples testing negative for methamphetamine during the trial.

FINDINGS

No statistically significant between-group differences were detected in urine drug test results, craving, treatment retention or adverse events.

CONCLUSIONS

The PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving.

Authors+Show Affiliations

University of California, Los Angeles, 90025, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22082089

Citation

Ling, Walter, et al. "Double-blind Placebo-controlled Evaluation of the PROMETA™ Protocol for Methamphetamine Dependence." Addiction (Abingdon, England), vol. 107, no. 2, 2012, pp. 361-9.
Ling W, Shoptaw S, Hillhouse M, et al. Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction. 2012;107(2):361-9.
Ling, W., Shoptaw, S., Hillhouse, M., Bholat, M. A., Charuvastra, C., Heinzerling, K., Chim, D., Annon, J., Dowling, P. T., & Doraimani, G. (2012). Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction (Abingdon, England), 107(2), 361-9. https://doi.org/10.1111/j.1360-0443.2011.03619.x
Ling W, et al. Double-blind Placebo-controlled Evaluation of the PROMETA™ Protocol for Methamphetamine Dependence. Addiction. 2012;107(2):361-9. PubMed PMID: 22082089.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. AU - Ling,Walter, AU - Shoptaw,Steven, AU - Hillhouse,Maureen, AU - Bholat,Michelle A, AU - Charuvastra,Charles, AU - Heinzerling,Keith, AU - Chim,David, AU - Annon,Jeffrey, AU - Dowling,Patrick T, AU - Doraimani,Geetha, Y1 - 2011/11/15/ PY - 2011/11/16/entrez PY - 2011/11/16/pubmed PY - 2012/5/2/medline SP - 361 EP - 9 JF - Addiction (Abingdon, England) JO - Addiction VL - 107 IS - 2 N2 - AIMS: To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence. DESIGN: A double-blind, placebo-controlled 108-day study with random assignment to one of two study conditions: active medication with flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg to day 40) and hydroxazine (50 mg to day 10) versus placebo medication (with active hydroxazine only). SETTING: Three substance abuse treatment clinics: two in-patient, one out-patient. PARTICIPANTS: Treatment-seeking, methamphetamine-dependent adults (n = 120). MEASUREMENTS: Primary outcome was percentage of urine samples testing negative for methamphetamine during the trial. FINDINGS: No statistically significant between-group differences were detected in urine drug test results, craving, treatment retention or adverse events. CONCLUSIONS: The PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving. SN - 1360-0443 UR - https://www.unboundmedicine.com/medline/citation/22082089/Double_blind_placebo_controlled_evaluation_of_the_PROMETA™_protocol_for_methamphetamine_dependence_ L2 - https://doi.org/10.1111/j.1360-0443.2011.03619.x DB - PRIME DP - Unbound Medicine ER -